Sartorius launches platform to boost efficiency in cell therapy production

Phase I data released from study of Lymphir dosing prior to commercial CAR T therapy in high‑risk diffuse large b‑cell lymphoma

Citius Oncology announced positive topline safety and efficacy results from an investigator‑initiated phase I trial evaluating Lymphir (E7777, denileukin diftitox‑cxdl) administered prior to commercial CD19‑directed CAR T therapy in patients with high‑risk relapsed or refractory diffuse large B‑cell lymphoma.

March 13, 2026

Vol.52 No.10

Clinical Roundup

Researchers create blueprint for designing CD8 killer T cells to kill cancer cells

Researchers have uncovered new genetic rules that determine how CD8 killer T cells choose between becoming long-lasting, protective defenders or slipping into exhausted, dysfunctional states.

February 06, 2026

Vol.52 No.05

Clinical Roundup

UTSW researchers boost the power of CAR T cells to fight cancer

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes engineered cancer-fighting immune cells behave more like stem cells, improving their therapeutic effectiveness. The study suggests new strategies for improving the efficacy of these immune cells, known as chimeric antigen receptor T cells.

January 30, 2026

Vol.52 No.04

Clinical Roundup

Sylvester researchers discover pathway that could explain prostate cancer resistance to ADT treatment

Researchers have discovered a previously unknown pathway that could explain why androgens remain and prostate cancer progresses despite treatment with androgen deprivation therapy.

December 12, 2025

Vol.51 No.45

Drugs & Targets

EC approves expanded use of CAR T-cell therapy Breyanzi for r/r mantle cell lymphoma

The European Commission has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor.

December 05, 2025

Vol.51 No.44

Clinical Roundup

Next-gen CAR T cells show promise at treating solid tumors, USC study shows

Using cell cultures and animal models, researchers from the USC Norris Comprehensive Cancer Center at Keck School of Medicine of USC showed that next-generation CAR T cells can safely and effectively shrink solid tumors.

October 10, 2025

Vol.51 No.37

Sartorius launches platform to boost efficiency in cell therapy production

YOU MAY BE INTERESTED IN

Phase I data released from study of Lymphir dosing prior to commercial CAR T therapy in high‑risk diffuse large b‑cell lymphoma

Researchers create blueprint for designing CD8 killer T cells to kill cancer cells

UTSW researchers boost the power of CAR T cells to fight cancer

Sylvester researchers discover pathway that could explain prostate cancer resistance to ADT treatment

EC approves expanded use of CAR T-cell therapy Breyanzi for r/r mantle cell lymphoma

Next-gen CAR T cells show promise at treating solid tumors, USC study shows

Renew today!

Subscriber content

Never miss an issue!

Login